Methylene Blue (USP grade)

Genuinely unique mechanism (alternative mitochondrial electron carrier that bypasses complex I/III blockade) with strict biphasic dosing — low dose helps, high dose hurts. A-tier only for rescue indications (methemoglobinemia, sepsis); B-tier for human memory/fear-extinction; biohacker community wildly overclaims healthy-adult cognitive benefit. For Dylan: OPTIONAL-ADD at MEDIUM confidence — mechanism fits the MMA subconcussive-impact + mitochondrial-load thesis, stacks cleanly with astaxanthin/ALCAR/idebenone, BUT (1) USP/pharma grade is non-negotiable (industrial and aquarium grades carry heavy-metal contamination), (2) the SSRI / serotonergic drug-interaction surface is a black-box-class hazard if Dylan ever adds bupropion or anything serotonergic, (3) G6PD deficiency must be ruled out via the June 2026 bloodwork before first dose, (4) blue urine/teeth/sclera staining is real and embarrassing. If trialed: 0.5-1 mg/kg once daily AM (~30-50 mg sublingual for Dylan) from a verified USP vendor (Health Natura / Body Bio / BlueBrainBoost), after baseline G6PD result is in.

Methylene blue (methylthioninium chloride, MTC) is a phenothiazine dye first synthesized in 1876 by Heinrich Caro at BASF. It has the unusual distinction of being the first fully synthetic drug ever used in medicine (Paul Ehrlich, malaria, 1891) and a chemical scaffold from which both the phenothiazine antipsychotics and the tricyclic antidepressants were later derived. Its modern medical use is rescue-only (methemoglobinemia, sepsis vasoplegia, ifosfamide encephalopathy) but it has accumulated a large 21st-century biohacker following on the basis of its mitochondrial mechanism and a small handful of suggestive cognitive trials.

The molecule has multiple distinct mechanisms, several of which matter for Dylan's profile:

1. Alternative mitochondrial electron carrier (the headline mechanism)

This is the mechanism the biohacker community is excited about, and it's real — but it's biphasic.

Methylene blue (MB) is freely interconverted between an oxidized blue form (MB+) and a reduced colorless form (leucoMB). In the mitochondrion it can:

• Accept electrons directly from NADH (bypassing complex I)
• Donate electrons directly to cytochrome c (bypassing complex III)
• Effectively act as a parallel electron-transport bypass for the standard ETC complexes when they are damaged or saturated.

The clinical implication: when complex I or III is blocked or damaged (by neurodegenerative pathology, ischemic injury, mitochondrial toxin, or — speculatively — repeated subconcussive impact), MB can keep oxidative phosphorylation running by routing electrons around the blockade. At the cellular level it has been shown to increase cytochrome c oxidase activity, increase oxygen consumption, increase ATP production, and increase glucose uptake in CNS neurons.

The biphasic / hormesis curve is the critical detail biohackers gloss over:

• Low dose (0.5-4 mg/kg, ~30-300 mg adult oral): Net antioxidant. Acts as electron carrier, increases ATP, scavenges singlet oxygen and lipid peroxyl radicals. This is the therapeutic window.
• High dose (>10 mg/kg, >700 mg adult): Net pro-oxidant. The same redox cycling that helps at low concentration starts generating reactive oxygen species at high concentration. Tissue MB exceeds the cellular reducing capacity, the equilibrium shifts toward sustained MB+ (oxidized) form, and the molecule becomes a source of oxidative stress rather than a sink.
• Very high doses (>15-20 mg/kg IV): Frank toxicity — methemoglobin generation, hemolysis (esp. in G6PD-deficient), serotonergic/neurologic effects, hypertensive crisis.

This is not a "more is better" compound. It's the cleanest example of a hormetic dose-response curve in the nootropic space. The biohacker default of "just take more" is actively counterproductive here — and the inflection appears to sit around 4-5 mg/kg in the rodent literature, which is uncomfortably close to typical aggressive biohacker doses scaled for body weight.

2. Reversible MAO-A inhibitor (the underrated mechanism)

Methylene blue is a clinically significant MAO-A inhibitor at routine doses. This is not a footnote — it's the source of the FDA black-box-class warning for serotonin syndrome when MB is co-administered with SSRIs. Per the FDA 2011 communication on perioperative MB use:

• IV doses as low as 1 mg/kg produce serotonin syndrome in patients on SSRIs.
• Oral nootropic doses (15-50 mg) produce smaller but real MAO-A inhibition — exact magnitude is dose-dependent, but the safety margin with concurrent serotonergic drugs is unknown and almost certainly thin.

For Dylan, this matters because:

• He is not currently on SSRIs (good).
• The V5 plan has bupropion (CYP2D6 inhibitor, mild dopaminergic, weak serotonergic at high doses) as an optional add. Co-administration of MB + bupropion is theoretically lower-risk than MB + SSRI but not zero-risk, and the FDA has clear language extending the warning to "any serotonergic drug."
• Modafinil's serotonergic activity is minimal; MB + modafinil has no documented serotonin-syndrome cases, but the pharmacology hasn't been formally evaluated.
• If Dylan ever adds an SSRI, SNRI, MAOI, triptan, tramadol, meperidine, fentanyl, or St. John's Wort: MB must be stopped first with a 5-week SSRI washout for fluoxetine, 2-week for shorter-half-life SSRIs.

The MAO-A inhibition also means MB carries mild antidepressant activity in its own right — small old trials at 15-300 mg/day reported antidepressant effects, plausibly consistent with MAO-A inhibition + mitochondrial energy support. Not Dylan's primary use case but worth flagging.

3. Soluble guanylate cyclase / nitric oxide synthase inhibitor

MB inhibits soluble guanylate cyclase (sGC) and several NOS isoforms. Clinically this is the sepsis-vasoplegia mechanism: by blocking the NO → cGMP → vasodilation cascade, MB raises blood pressure in patients with refractory vasoplegic shock. It's also why high-dose MB can cause hypertensive crises in healthy users — an off-target consequence of the same mechanism.

For Dylan: at low oral doses (15-50 mg) this effect is sub-clinical for blood pressure in healthy young adults. But it's worth knowing that MB is mildly vasoconstrictive — not a tool for someone with hypertension, and not worth stacking with stimulants in a way that compounds blood-pressure load.

4. Tau / alpha-synuclein aggregation modulation

MB and its derivatives (especially LMTM = leuco-methylthioninium-bis-hydromethanesulfonate) inhibit tau filament formation in vitro and in cell culture — by directly binding tau in a configuration that prevents pathological self-association. This was the rationale for TauRx Pharmaceuticals' Phase 3 trials of LMTM (TRx0237) in Alzheimer's disease (TRX-237-005, 2016) and frontotemporal dementia.

Both Phase 3 trials failed their primary endpoints. The 2016 Lancet paper showed no benefit of LMTM monotherapy over the (very-high-dose) placebo control in mild-to-moderate AD; the FTD trial similarly failed. A 2018 reanalysis suggested possible benefit in monotherapy subjects (vs. those on background AD drugs) but this was a post-hoc finding from a failed primary. The mechanism remains elegant; the clinical translation has not held up.

For Dylan: the tau-aggregation angle is theoretically relevant to repeated subconcussive impact (CTE pathology is tau-driven) but no human evidence supports MB as TBI/CTE prophylaxis. This is the speculative-but-mechanistically-coherent piece of the rationale.

5. Antioxidant + lipid peroxidation defense (overlaps idebenone / astaxanthin)

At low concentrations MB scavenges singlet oxygen, hydroxyl radicals, and lipid peroxyl radicals — overlapping with idebenone (cytoplasmic + membrane antioxidant) and astaxanthin (membrane-spanning antioxidant). The mechanism is similar in principle (redox-active small molecule), different in distribution (MB freely crosses BBB, distributes broadly intracellularly, accumulates in mitochondria via positive charge attraction to mitochondrial membrane potential).

This is part of why MB stacks well in principle with idebenone and astaxanthin — the three operate at slightly different membrane depths and via different upstream mechanisms (idebenone is NQO1-activated and enters at complex III; MB is electrochemically reduced and bypasses complex I; astaxanthin is structural and bilayer-spanning). They are layered, not redundant. The catch: there is zero clinical data on the three in combination — extrapolation only.